US Patent 7696161 Exendin agonist compounds
Patent 7696161 was granted and assigned to Amylin Pharmaceuticals on April, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 30 Oct, 2023
Golden AI
Edits made to:
Article (+220 characters)
Article
Patent abstract
Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07696161 Exendin agonist compounds US Patent 7696161 Exendin agonist compounds
Infobox
Patent Number
0769616100
Patent Number
769616100
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076961610
Date of Patent
April 13, 2010
0Patent Application Number
118070310
Date Filed
May 25, 2007
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076961610
Date of Patent
April 13, 2010
0Patent Application Number
118070310
Date Filed
May 25, 2007
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07696161 Exendin agonist compounds
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07696161
Date of patent
April 13, 2010
Patent application number
11807031
Date Filed
May 25, 2007
Patent primary examiner
Find more entities like US Patent 7696161 Exendin agonist compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
